Oman Pharmaceuticals & Healthcare Report Q4 2006
DUBLIN, Ireland--Research and Markets (http://www.researchandmarkets.com/reports/c60951) has announced the addition of Oman Pharmaceuticals & Healthcare Report Q4 2006 to their offering.
The Oman Pharmaceuticals & Healthcare Report provides independent forecasts and competitive intelligence on Oman's pharmaceuticals & healthcare industry.
Oman has one of the most efficient healthcare systems in the Middle East & North Africa (MENA) region. This rapid growth (of around 10% per annum) of its pharmaceutical market is being driven predominately by a rapid increase in population and the growing contribution of the private sector, stimulated by the exclusion of expatriate workers from public healthcare schemes and the increased demand for medical tourism. Prescription and branded drugs continue to dominate the market, standing at more than 90% and 95% of the total value, respectively.
The recent Oman-US Free Trade Agreement (FTA) has also resulted in a marked improvement in Oman's intellectual property (IP) rights legislation, including the implementation of a data exclusivity regime and tougher penalties for counterfeiters. This will serve to further boost import opportunities, especially for treatments of chronic diseases. However, the drug regulatory system in Oman is still considered to be below international standards, with multinational drugmakers claiming that it is opaque and somewhat arbitrary and that it unfairly provides high levels of protection to local manufacturers. Plans to harmonise the drug regulation process in the GCC could help standardise procedures in the country.
The adjusted Business Environment Rankings for the MENA region reveal that the Oman is in joint fourth place behind Saudi Arabia, Kuwait and South Africa. This is primarily due to forecasts of high market growth (of around 10% per annum), coupled with the country's new intellectual property regime. Oman's limited domestic manufacturing industry and lack of technological capabilities have also made the country an excellent investment opportunity for foreign drugmakers, although the outlook is tempered somewhat by the small overall market size.
Development in the country's healthcare sector could increasingly focus on the provision of outsourced pharmaceutical production as the GCC begins to challenge markets such as India and China in this field. Gulf drugmakers have the advantage of being able to offer low-cost drugs, which have been manufactured to a high standard. Local player Oman Pharmaceutical Products Company (OPPC) is attempting to exploit this avenue through offering contract manufacturing to multinationals.
Content Outline:
Executive Summary
Oman Pharmaceuticals & Healthcare Industry SWOT
Oman Political SWOT Industry SWOT
Oman Economic SWOT
Oman Business Environment SWOT
Oman: Business Environment Ranking
Table: Business Environment Ranking: Middle East & Africa
Business Environment Ranking
Economics - Long-Term Risk
Politics - Long-Term Risk
Regulatory Barriers
Domestic Sector Threat
Market Growth Potential
Market Size Ranking
Market Summary
Regulatory Regime
Intellectual Property Developments
Table: Current IP Laws In Oman
Pricing & Reimbursement
Regional Price Harmonisation
Public Sector Drug Procurement
Free Trade Agreements (FTAs)
Industry Developments
Healthcare Sector
Private Healthcare Sector
Health Profile
Table: Oman Mortality Indicators (2004)
Healthcare Reforms
Table: Geographical Distribution Of Health Centres
Medical Tourism
International Collaboration
Pharmaceutical Sector
International Pharmaceutical Collaboration
Table: India's Export Of Pharmaceutical Products To The GCC Countries 2001-2005 (US$mn)
Industry Forecast Scenario
Overall Market Forecasts
Table: Other Healthcare Data Forecasts
Key Growth Factors - Industry
Table: Drug Expenditure Forecasts
Key Growth Factors - Macroeconomic
Table: Oman: Macroeconomic Data And Forecasts
Prescription Market Forecast
Table: Prescription Drug Market Forecasts
OTC Market Forecast
Table: OTC Market Forecasts
Generics And Branded Market Forecast
Table: Generics And Branded Market Forecasts
Export/Import Market Forecasts
Table: Import/ Domestic Output Forecasts
Other Healthcare Data Forecasts
Table: Other Healthcare Data forecast
Key Risk To BMI's Forecasts
Competitive Landscape
Company Monitor
Indigenous Manufacturers
Oman Pharmaceutical Products Co (OPPC)
National Pharmaceutical Industries (NPI)
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Appendix: Regional Demographic Data
The Long View: Data Over The Economic Cycle (2000-2007)
Population
Household Spending Per Capita, US$
Private Consumption Per Capita, US$ PPP
Market Size, GDP, USDbn
Country Snapshot: Oman Demographic Data
Section 1: Population
Table: Demographic Indicators (2005)
Table: Rural/Urban Breakdown
Section 2: Education & Healthcare
Table: Education
Table: Healthcare: Vital Statistics
Table: Healthcare: Expenditure
Section 3: Labour Market And Spending Power
Table: Employment Indicators
Table: Consumption And Stratification
Companies Mentioned:
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co
- Novartis
- Pfizer
- Sanofi-Aventis
For more information visit http://www.researchandmarkets.com/reports/c60951
Contacts
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com
The Oman Pharmaceuticals & Healthcare Report provides independent forecasts and competitive intelligence on Oman's pharmaceuticals & healthcare industry.
Oman has one of the most efficient healthcare systems in the Middle East & North Africa (MENA) region. This rapid growth (of around 10% per annum) of its pharmaceutical market is being driven predominately by a rapid increase in population and the growing contribution of the private sector, stimulated by the exclusion of expatriate workers from public healthcare schemes and the increased demand for medical tourism. Prescription and branded drugs continue to dominate the market, standing at more than 90% and 95% of the total value, respectively.
The recent Oman-US Free Trade Agreement (FTA) has also resulted in a marked improvement in Oman's intellectual property (IP) rights legislation, including the implementation of a data exclusivity regime and tougher penalties for counterfeiters. This will serve to further boost import opportunities, especially for treatments of chronic diseases. However, the drug regulatory system in Oman is still considered to be below international standards, with multinational drugmakers claiming that it is opaque and somewhat arbitrary and that it unfairly provides high levels of protection to local manufacturers. Plans to harmonise the drug regulation process in the GCC could help standardise procedures in the country.
The adjusted Business Environment Rankings for the MENA region reveal that the Oman is in joint fourth place behind Saudi Arabia, Kuwait and South Africa. This is primarily due to forecasts of high market growth (of around 10% per annum), coupled with the country's new intellectual property regime. Oman's limited domestic manufacturing industry and lack of technological capabilities have also made the country an excellent investment opportunity for foreign drugmakers, although the outlook is tempered somewhat by the small overall market size.
Development in the country's healthcare sector could increasingly focus on the provision of outsourced pharmaceutical production as the GCC begins to challenge markets such as India and China in this field. Gulf drugmakers have the advantage of being able to offer low-cost drugs, which have been manufactured to a high standard. Local player Oman Pharmaceutical Products Company (OPPC) is attempting to exploit this avenue through offering contract manufacturing to multinationals.
Content Outline:
Executive Summary
Oman Pharmaceuticals & Healthcare Industry SWOT
Oman Political SWOT Industry SWOT
Oman Economic SWOT
Oman Business Environment SWOT
Oman: Business Environment Ranking
Table: Business Environment Ranking: Middle East & Africa
Business Environment Ranking
Economics - Long-Term Risk
Politics - Long-Term Risk
Regulatory Barriers
Domestic Sector Threat
Market Growth Potential
Market Size Ranking
Market Summary
Regulatory Regime
Intellectual Property Developments
Table: Current IP Laws In Oman
Pricing & Reimbursement
Regional Price Harmonisation
Public Sector Drug Procurement
Free Trade Agreements (FTAs)
Industry Developments
Healthcare Sector
Private Healthcare Sector
Health Profile
Table: Oman Mortality Indicators (2004)
Healthcare Reforms
Table: Geographical Distribution Of Health Centres
Medical Tourism
International Collaboration
Pharmaceutical Sector
International Pharmaceutical Collaboration
Table: India's Export Of Pharmaceutical Products To The GCC Countries 2001-2005 (US$mn)
Industry Forecast Scenario
Overall Market Forecasts
Table: Other Healthcare Data Forecasts
Key Growth Factors - Industry
Table: Drug Expenditure Forecasts
Key Growth Factors - Macroeconomic
Table: Oman: Macroeconomic Data And Forecasts
Prescription Market Forecast
Table: Prescription Drug Market Forecasts
OTC Market Forecast
Table: OTC Market Forecasts
Generics And Branded Market Forecast
Table: Generics And Branded Market Forecasts
Export/Import Market Forecasts
Table: Import/ Domestic Output Forecasts
Other Healthcare Data Forecasts
Table: Other Healthcare Data forecast
Key Risk To BMI's Forecasts
Competitive Landscape
Company Monitor
Indigenous Manufacturers
Oman Pharmaceutical Products Co (OPPC)
National Pharmaceutical Industries (NPI)
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Appendix: Regional Demographic Data
The Long View: Data Over The Economic Cycle (2000-2007)
Population
Household Spending Per Capita, US$
Private Consumption Per Capita, US$ PPP
Market Size, GDP, USDbn
Country Snapshot: Oman Demographic Data
Section 1: Population
Table: Demographic Indicators (2005)
Table: Rural/Urban Breakdown
Section 2: Education & Healthcare
Table: Education
Table: Healthcare: Vital Statistics
Table: Healthcare: Expenditure
Section 3: Labour Market And Spending Power
Table: Employment Indicators
Table: Consumption And Stratification
Companies Mentioned:
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co
- Novartis
- Pfizer
- Sanofi-Aventis
For more information visit http://www.researchandmarkets.com/reports/c60951
Contacts
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.